DYN: SEC Form 4 filed by Dyne Therapeutics Inc.

Historical context for DYN

Across the 28 sessions after earlier DYN headlines, the stock closed higher 17 times and lower 11 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

Earlier insider filings at DYN

• Oct 6, 2026Director Posner Brian S bought $40,000 worth of shares (2,500 units at $16.00) (SEC Form 4)
• Sep 8, 2026Chief Commercial Officer Friedl-Naderer Johanna sold $25,408 worth of shares (1,085 units at $23.42) as part of a pre-agreed trading plan, decreasing direct ownership by 0.70% to 152,897 units (SEC Form 4) to cover taxes
• Sep 8, 2026Chief Medical Officer Kerr Douglas sold $115,546 worth of shares (5,035 units at $22.95) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 162,564 units (SEC Form 4) (for withholding tax)
• Sep 8, 2026CEO & President Cox John sold $106,823 worth of shares (5,658 units at $18.88) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 357,507 units (SEC Form 4) (tax withholding)
• Aug 17, 2026Director Rhodes Jason P sold $65,184,894 worth of shares (2,586,928 units at $25.20) as part of a pre-agreed trading plan (SEC Form 4)